Suit alleges that J&J made "false claims regarding the efficacy of Nubeqa," Bayer's drug that former NFL quarterback Tony ...

Nubeqa and Kerendia—are performing even better than the company anticipated and their momentum is expected to continue in 2026. | The primary growth drivers in Bayer’s pharma sector—Nubeqa and ...

By Jonathan Stempel NEW YORK, Feb 23 (Reuters) - Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely ...

Bayer has filed a false advertising lawsuit taking issue with claims made by Johnson & Johnson to pit their prostate cancer drugs against one another. | Bayer has filed a false advertising lawsuit ...

Bayer filed a lawsuit against Johnson & Johnson and its Janssen Biotech unit, alleging that marketing claims regarding the superiority of J&J's Erleada prostate-cancer drug versus Bayer's Nubeqa are ...

Nubeqa plus ADT improved HRQoL and delayed pain progression in mHSPC patients, outperforming placebo plus ADT. The FDA approved Nubeqa for mHSPC based on ARANOTE trial data, highlighting its clinical ...

Bayer's Nubeqa gains approval in India for non-chemotherapy treatment of advanced prostate cancer, enhancing patient care ...

Bayer sued Johnson and Johnson, alleging false advertising for its prostate cancer drug Erleada, claiming it misleads patients.

Investing.com - Bayer AG filed a lawsuit Monday in New York federal court accusing Johnson & Johnson of making false and misleading claims in advertisements for its prostate cancer drug Erleada, ...

Bayer has filed a lawsuit against Johnson & Johnson and Janssen Biotech, alleging the companies made false and misleading claims about the efficacy of its prostate cancer drug Nubeqa compared to the ...